Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

摘要: Combination of chemotherapeutic agents and angiogenesis inhibitors is now commonly employed in the clinic to treat cancer. Here, we used angiostatic anginex 0118, combination with irofulven, human ovarian tumor xenografts mice. General linear mixed models were statistically analyze growth curves. Overall, a low, non-toxic dose irofulven either inhibitor was more effective at inhibiting than any single agent therapies. For example, anginex/irofulven 0118/irofulven combinations inhibited relative controls by 92% (p < 0.0001) 96% 0.0001), respectively, yielding 100% complete responses. This study suggests that therapy 0118 or may be highly clinical setting.